Streetbeat News

Revenues

GWW

Seven financial analysts have recently updated their ratings on W.W. Grainger (NYSE:GWW), showing a shift towards a more positive outlook with an average 12-month price target of $958.86, up from $864.00. The updates include raised price targets from analysts at Oppenheimer, Loop Capital, JP Morgan, Stephens & Co., RBC Capital, and Jefferies, reflecting changes in market conditions and company performance. W.W. Grainger, a major distributor of maintenance and repair products, has shown solid revenue growth and strong financial health, despite a net margin below industry averages.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 1:00 pm

GBTG

American Express Global Business Travel, a part of Global Business Travel Group (GBTG), forecasts its FY24 revenue to be between $2.43B and $2.50B, which is slightly below the estimated $2.51B.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:51 pm

GBTG

Global Business Travel (NYSE:GBTG) reported Q4 sales of $549.00M, surpassing the analyst consensus estimate of $541.17M by 1.45% and marking a 4.17% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:49 pm

STIM

Neuronetics projects Q1 FY 2024 sales to be between $16.7M-$17.7M and full-year sales to reach $78M-$80M, aligning closely with consensus estimates of $16.98M for Q1 and $78.64M for the year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:33 pm

ABBV

Dragonfly Therapeutics has received a milestone payment after the first patient was dosed in a clinical trial by AbbVie. The trial is evaluating ABBV-303, a treatment targeting solid tumors. This development marks a significant step in the collaboration between Dragonfly Therapeutics and AbbVie, potentially impacting the progress and valuation of ABBV-303.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:17 pm

AXGN

Axogen projects its 2024 revenue to be between $177M and $181M, marking an 11%-14% increase, aligning closely with the consensus estimate of $179.22M. The company also anticipates a gross margin of 76%-79% for the same period.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:12 pm

MASS

908 Devices projects its FY24 revenue to be between $52M-$54M, indicating a 4%-8% growth YoY, which is below the previous expectation of $55.51M.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:07 pm

MCRB

Seres Therapeutics, Inc. (MCRB) announced its current cash balance of $128M, along with planned savings from a restructuring announced in November 2023. Assuming continued revenue growth from its product Vowst and the expected receipt of a $45M Tranche B under its secured debt, the company expects to support its operations into Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:07 pm

RAND

Rand Capital (NASDAQ:RAND) reported a slight decrease in its Q4 adjusted EPS to $0.40 from $0.41 YoY, while sales increased by 11.37% to $1.93M from $1.73M YoY.

Portfolio Pulse from mahesh@benzinga.com

March 05, 2024 | 12:04 pm

FWRG

First Watch Restaurant Gr (FWRG) reported Q4 2023 earnings of $0.040 per share, meeting analyst estimates. Quarterly sales were $244.633M, surpassing the $237.527M estimate by 2.99% and marking a 31.70% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 12:02 pm